+ T cells in the tumor microenvironment display reduced functionality and hyporesponsiveness. TGF-contributed markedly to the tumor-inWltrating CD8 + T cells' (TILs) reduced functionality, which could be reversed using a small molecule TGF-inhibitor. Upon T-cell receptor (TCR) activation, the activation of ITK and ERK kinases were reduced in CD8 + TILs, as compared to splenic CD8 + T cells: TGFinhibitor could reverse this phenomenon. This study demonstrates for the Wrst time the association of the Spred-1 gene, an inhibitor of the Ras/MAPK pathway, with CD8 + TILs and TGF-activity. Spred-1 was upregulated in CD8 + TILs and TGF-enhanced the expression of Spred-1 in eVector/memory CD8 + T cells and not in rested/memory CD8 + T cells. Based on these Wndings, this study supports the hypothesis that TGF-mediates an inhibitory mechanism on CD8 + TILs involving TCR-signaling blockade and the upregulation of Spred-1, thus implicating Spred-1 as a potential new target for future anti-tumor immune studies.
Introduction
T cells speciWc for tumor antigens have been identiWed both within the tumor itself and in the peripheral blood of cancer-bearing individuals. A number of studies on tumorassociated CD4 + T cells have revealed a T-cell-speciWc hyporesponsiveness related to the T-cell receptor (TCR) signaling pathway [1] [2] [3] [4] [5] [6] [7] . Moreover, other studies have similarly demonstrated impairment of functionality in CD8 + T cells in tumors [8] [9] [10] [11] [12] . A number of biologically active agents synthesized by either tumor or stromal cells, such as TGF-, exert suppressive eVects on the immune system [13] .
Transforming growth factor (TGF-) is a pleiotropic immunosuppressive cytokine that inhibits T-cell activation, proliferation and diVerentiation [14] . It has been shown that TGF-is produced by many diVerent tumors and it has been suggested that its immunosuppressive eVects may contribute to the failure of tumor-associated T cells to control tumor progression [15, 16] . These phenomena might explain how tumors escape immune recognition. Elevated TGF-expression in the tumor microenvironment modulates a complex web of intercellular interactions that promotes metastasis and progression [17] . TGF-not only exerts its inXuence on the hyporesponsiveness of CD4 + and CD8 + T cells in the tumor microenvironment, but also regulates the development and function of other leukocytes, including regulatory T cells, dendritic cells, NK and B cells [14] . TGF-can induce the transformation of normal eVector cells into regulatory T cells by inducing the expression of Foxp3 through the inactivation of ERK [18, 19] . TGFmay also actively subvert the CD8 + T cells into directly promoting tumor growth by producing IL-17, an apoptosis suppressor of tumor cell lines in vitro [20] . Moreover, membrane-associated TGF-has been demonstrated to be involved in the blockade of the TCR signaling pathway of memory T cells in the tumor microenvironment and nonmalignant inXammatory microenvironment [21] . In vitro studies have shown that the TGF-signaling pathway intersects with and modulates the TCR signaling pathway through the inactivation of TCR signaling components like the inactivation of IL2-inducible T-cell kinase (ITK) and inhibition of ERK phosphorylation in activated CD4 + T cells from non-tumor-bearing mice [13, 22] . However, the role of TGF-in the molecular mechanism that aVects the TCR signaling hyporesponsiveness of T cells in the tumor microenvironment is still not well established.
A recent study has characterized Spred-1 (Sproutyrelated Ena/VASP homology 1-domain-containing protein-1) as a novel protein involved in the inhibition of the Ras/ Raf-1/ERK pathway impairing the growth-factor-mediated activation of ERK1/2 kinases. It has been shown that Spred-1 speciWcally potentiates the interaction between activated Ras and Raf creating a Spred-Ras-Raf complex. This complex prevents Raf activation by Raf kinase, thus suppressing the activation of the downstream pathway [23] . The negative eVect of Spred-1 on the Ras-MAP kinase pathway was investigated Wrst in muscle cell lines and brain tumor cells and then in a variety of other cells like human hepatocellular carcinomas as well as hematopoietic cells [23] [24] [25] . In this study we have deWned, for the Wrst time, the overexpression of the Ras/MAPK inhibitor Spred-1 in tumor-associated CD8 + T cells and we have correlated Spred-1 expression with TGF-activity. The data reported here thus provide evidence that TGF-plays an important role in impairing the functionality of tumor-inWltrating CD8 + T cells (TILs), which then lose their ability to respond to TCR stimulation. Moreover, Spred-1 can play an important role in the action of TGF-to induce anergy in tumor-inWltrating CD8 + T cells.
Materials and methods

Tumor model
All animal studies were approved by the 
Proliferation assay
To perform the proliferation assay of CD8 + T cells from tumor inWltrate and from spleens of control and tumor-bearing mice, mice were sacriWced 3 weeks after tumor implant. Tumors were removed and digested (as described in Ref. [26] ). Cells were stained for CD8 and, using a FACSVantage Xow cytometer (BD Biosciences), CD8 + cells were puriWed. Splenic CD8 + T cells preparation and proliferation assays were set up as described in Ref. [7] .
Flow cytometry
Cells from spleen and tumor were stained with Ab against CD8 (53-6.7), purchased from BD Biosciences. For BrdU studies, in vitro labeling of the cells was performed adding BrdU to the cell culture at a Wnal concentration of 10 M for 6 h. Following cell-surface marker staining, cells were stained for BrdU incorporation using the BrdU Flow Kit from BD Biosciences and anti-BrdU (B44).
For CFSE assay, cells were labeled with CFSE: cells were washed twice with PBS, incubated with 1 M CFSE in PBS for 10 min at 37°C and washed twice with PBS.
For intracellular staining of pITK (pY551) and pERK1/2 (pT202/pY204), speciWc antibodies were purchased from BD Biosciences. Single-cell suspensions from the spleen and tumor inWltrate were prepared and incubated for 24 h in vitro. Cells were treated with Fc block for 15 min on ice. For the activation of pITK, cells were incubated with 10 g/ml anti-CD3 (BD Biosciences) for 20 min on ice. The single-cell suspensions were then incubated in a 37°C waterbath for 5 min before adding 60 g/ml goat anti-hamster cross linker (Jackson Immunoresearch) for 1 min. For activation of pERK 1/2, cells were incubated in a 37°C waterbath with PMA/Ionomycin (15 ng/ml/850 nM) for 15 min. After activation, cells were Wxed, permeabilized and stained for pITK or pERK 1/2 for 1 h at room temperature in the dark. The samples were then analyzed on a FACSCalibur Xow cytometer (BD Biosciences). Data were analyzed using CellQuest software (BD Biosciences) and gates were placed on CD8 + cells.
Detection of intracellular cytokines
For intracellular detection of cytokine production, cells were incubated at 37°C in a CO 2 Spleens from F5 transgenic mice were removed and pressed through a 70-m Wlter to obtain a total splenocytes cell suspension. EVector/memory CD8 + T cells were generated incubating in culture the total splenocytes with 10 ¡4 g/ml NP-68 peptide for 3 days. A CD8 positive selection was then performed using anti-CD8 microbeads from Miltenyi Biotec, according to the manufacturer's protocol.
Rested/memory CD8 + T cells were generated by culturing the total splenocytes with 10 ¡4 g/ml NP-68 peptide for 3 days. After 3 days, the live cells were collected using centrifugation with Ficoll gradient, washed and rested for 14 days in six-well plates with 140 ng/ml of murine IL-15 in medium. The cells were washed and given IL-15 every 3 days. A CD8 positive selection was then performed as described above.
Expression analysis by real-time PCR RNA was isolated from cells using a NucleoSpin RNA II Kit (Macherey-Nagel). cDNA was prepared using 0.5 g of RNA with the high capacity RNA-to-cDNA kit (Applied Biosystems). The real-time PCRs were performed using TaqMan Gene Expression Master Mix (Applied Biosystems) and TaqMan Gene Expression Assays for mouse Spred-1 (FAM) and mouse GAPD (VIC) as housekeeping gene (Applied Biosystems). The reaction was performed using the 7300 Real-Time PCR System apparatus (Applied Biosystems). Cycling conditions were 52°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15 s and 60°C for 1 min. The results were analyzed using the Ct formula.
Statistics
Data are presented as the mean § SD. The signiWcance of the diVerence between groups was evaluated with Student's t test; P < 0.05 was considered signiWcant.
Results
Tumor-inWltrating CD8 + T cells are functionally impaired
In order to investigate the functionality of the tumor-inWltrating lymphocytes (TILs), MC38 cells were implanted subcutaneously and 3 weeks later TILs were compared to CD8 + T cells from spleens of either control mice or tumorbearing mice. This tumor produced high levels of TGF-, as shown in Fig. S1 .
To address the functionality of CD8 + T cells, the proliferation of splenic CD8 + T cells from control mice and from tumor-bearing mice was compared to TILs 24 h post-TCR activation. While splenic CD8 + T cells from control and tumor-bearing mice showed a similar level of proliferation, tumor-inWltrating CD8 + T cells showed a signiWcantly reduced proliferation as compared to the controls ( Fig. 1a , P < 0.005).
Moreover, tumor-inWltrating CD8 + T cells demonstrated a reduced ability to produce cytokines such as TNF-, IL-2 and IFN-, compared to splenic CD8 + T cells isolated from tumor-bearing spleen after 24 h of TCR activation in vitro (Fig. 1b) . These data collectively demonstrated that in an MC38 tumor model TILs displayed a hyporesponsive (anergic) status compared to splenic CD8 + T cells of either control or tumor-bearing mice.
Role of TGF-in the induction of anergy of CD8 + T cells in vitro
To investigate the direct eVect of TGF-on CD8 + T cells, normal unfractionated splenocytes were incubated with or without TGF-for 24 h. CD8 + T cells were puriWed, CFSE labeled and activated in the presence of anti-CD3 and irradiated APCs for an additional 24 h. As depicted in Fig. 2a, CD8 + T cells that were treated with TGF-lagged in cell cycle progression both at 24 h (left panels) and strongly at 72 h post-activation (right panels). INF-production was also measured by intracellular staining 24 h post-TCR activation in CD8 + T cells from splenocytes cultured with or without TGF-. Treatment with TGFled to a reduction in the number of CD8 + T cells that produced INF-(from 10.9 to 3.5%, Fig. 2b ). These data suggest that TGF-treatment in vitro indeed aVected CD8 + T cells and reduced the responsiveness of CD8 + T cells to TCR stimulation.
Inhibition of TGF-partially restored tumor-inWltrating CD8 + functionality ex vivo
To further investigate the eVect of TGF-in establishing the anergic state of CD8 + T cells in the tumor microenvironment, a small molecule TGF-inhibitor (speciWc inhibitor of the TGF-receptor I activity) was used on ex vivo MC38 total tumor digestion. Three-week s.c. tumors were removed and digested to a single cell suspension. The total tumor digest, in which the TILs were also present, was incubated for 24 h in vitro with 5 M TGF-inhibitor SB505124 or with its solvent DMSO as control. The functionality of the tumor-inWltrating CD8 + T cells, in the presence or absence of SB505124, was measured by BrdU incorporation and intracellular IFN-production after TCR activation by the addition of anti-CD3 in the total cell suspension (containing APCs). As depicted in Fig. 3 , the BrdU incorporation by the TILs treated with TGF-inhibitor SB505124 was increased compared with the same cells incubated with DMSO (Fig. 3a) . The incubation of the total tumor digestion for 24 h with TGF-inhibitor SB505124 also led to an increase in INF-production by the TILs as shown by intracellular staining (Fig. 3b) . These results demonstrated that the inhibition of TGF-activity by a small molecule inhibitor for only 24 h in vitro could partially reinstate the functionality of the tumor-inWltrating CD8 + T cells. Based on these observations, it can be concluded that TGF-is an active player in the induction of anergy in CD8 + T cells inside the tumor.
Tumor-inWltrating CD8 + T cells downregulate gene expression of molecules involved in TCR signaling and T-cell proliferation
The results of the microarray analyses conducted on the individual gene level demonstrated that the mRNAs of many molecules involved in proximal and distal TCR signaling pathway were downregulated in the tumorinWltrating CD8 + T cells as compared with CD8 + T cells from the spleen of tumor-bearing mice (Table S1 ). The altered mRNA expression of CD3 and TCR in microarray results was further conWrmed on a protein level by FACS analysis of cell-surface staining (Table S2) . To assess the level of ITK phosphorylation following TCR activation, intracellular staining of phospho-ITK was performed. MC38 tumor digest and unfractionated splenocytes from tumor-bearing mice were incubated for 24 h in vitro with DMSO or TGF-inhibitor SB505124 and then activated through the TCR with anti-CD3 and crosslinker. As depicted in Fig. 4 , phospho-ITK was detected by intracellular staining using FACS analysis. CD8 + T cells from the tumor suspension did not show any increase in phospho-ITK after TCR stimulation (middle panel, Fig. 4) as Fig. 4) . The presence of the TGF-inhibitor SB505124 in the culture was able to restore the phosphorylation of ITK after TCR stimulation (bottom panel, Fig. 4) . These results parallel with the microarray analysis demonstrating that the downregulation of TCR pathway components, in tumorinWltrating CD8 + T cells, corresponds to impairment in phosphorylation of ITK, a proximal event in the TCR signaling cascade. Moreover, TGF-activity seems to play a role in the impaired phosphorylation of ITK in CD8 + TILs.
Spred-1, an inhibitor of the activation of ERK/MAPK kinase, is upregulated in tumor-inWltrating CD8 + T cells in a TGF--dependent manner
At the individual gene level, microarray analysis demonstrated that Spred-1 expression is highly upregulated in the TILs as compared with normal CD8 + T cells from tumorbearing mice (70-fold, Table S1 ). Additionally, real-time PCR conWrmed that the expression of Spred-1 was markedly upregulated (P < 0.005) in these cells as depicted in Fig. 5a .
Since tumor-inWltrating CD8 + T cells showed altered proliferation and cytokine production compared with splenic CD8 + T cells from tumor-bearing mice, we focused our attention on a single gene, Spred-1, which has been shown to inhibit the activation of the ERK/MAPK pathway. To investigate whether TGF-plays a role in Spred-1 upregulation in CD8 + T cells in the tumor microenvironment, MC38 tumors were digested to a single cell suspension. In order to generate a large number of CD8 + T cells that have been exposed to tumor cells, additional normal puriWed splenic CD8 + T cells were cultured together with the tumor digest (to allow the puriWcation of a high number of CD8 + T cells after treatment for real-time PCR assay). TGF-inhibitor SB505124 was added to the mixed cell culture 24 h before the addition of anti-CD3, which triggers the TCR activation. After 24 h of activation, the CD8 + T cells were puriWed from the mixed culture and real-time PCR was performed. The inhibition of the endogenous TGF-activity by the inhibitor SB505124 led to a signiWcant reduction (P < 0.005) of Spred-1 expression in CD8 + T cells in a dose-dependent manner compared to the DMSO control (Fig. 5b) . These data demonstrated that TGFcould directly upregulate Spred-1 expression in CD8 + T cells.
To further investigate the eVect of TGF-on Spred-1 expression in CD8 + T cells, three diVerent populations of CD8 + T cells were treated: naive, eVector/memory, and rested/memory CD8 + T cells. These cells were incubated with TGF-in vitro for 24 h and the expression of Spred-1 was examined by real-time PCR. As depicted in Fig. 5c , Spred-1 was slightly upregulated (P < 0.05) in the presence of TGF-in the naive CD8 + T cells as compared to the same cells incubated with media without TGF- (Fig. 5c, left panel) . TGF-treatment led to enhanced upregulation (P < 0.005) of Spred-1 in the eVector/memory CD8 + T cells (Fig. 5c, middle panel) , whereas the expression of Spred-1 did not change in the rested/memory CD8 + T cells post-TGF-treatment (Fig. 5c, right panel) . Therefore, our in vitro data demonstrated that TGFcould directly upregulate Spred-1 primarily in eVector/ memory CD8 + T cells. Since it has been previously shown that Spred-1 can inhibit the activation of ERK kinase pathway in neuronal and muscle cell lines [23] , we investigated the consequences of the upregulation of Spred-1 on ERK kinase phosphorylation following TCR activation in tumor-inWltrating CD8 + T cells. To address the role of Spred-1 in the activation of ERK in tumor-inWltrating CD8 + T cells, MC38 tumor digest and unfractionated splenocytes from the tumor-bearing mice were incubated in vitro for 24 h with DMSO or TGF-inhibitor SB505124 and then activated with PMA/ Ionomycin, which mimics full activation by TCR signaling. Following this, intracellular staining for phospho-ERK was performed using FACS analysis. ERK phosphorylation in CD8 + T cells from the tumor inWltrate was markedly reduced as compared to CD8 + T cells from the spleen (Fig. 6, top and middle pannel) . However, the treatment of tumor single cell suspension with TGF-inhibitor could restore the phosphorylation of ERK in CD8 + TILs after PMA/Ionomycin activation (Fig. 6, bottom panel) .
These results demonstrated that CD8 + TILs present a low level of ERK phosphorylation following TCR activation and this response is linked to the TGF-activity. This outcome might explain the impaired proliferation responses of the TILs upon TCR activation.
Discussion
In this study we have established that CD8 + T cells present in the tumor microenvironment displayed impaired functionality and hyporesponsiveness to TCR stimulation in the presence of TGF-. We have shown that the inhibition of TGF-activity, using a speciWc small molecule inhibitor SB505124 [27] , can reverse the anergic state of ex vivo tumor-inWltrating CD8 + T cells. This result suggests that TGF-is one of the cytokines that leads to impaired functionality of CD8 + T cells in the tumor microenvironment. To explore possible molecular mechanisms involved in the altered functionality of the TILs, we examined changes at the gene level in these cells. Microarray analysis of the TILs revealed that many genes involved in TCR signaling pathway were altered in tumor-associated CD8 + T cells in accordance with previous reports [1, 28] . In our study we have reported that TCR chains and signaling molecules required for TCR signal transduction, such as TCR beta chain, CD3 zeta chain, ZAP70 and ITK, are downregulated in tumor-inWltrating CD8 + T cells. Another cell-surface molecule overexpressed on the CD8 + TILs' surface + T cells is LAG-3: it has already been shown, using two murine systems, that LAG-3 is involved in the maintenance of the tolerance to self and tumor antigens via direct eVects on CD8 + T cells [29] . Previously, it has been demonstrated using confocal microscopy that TGF-impaired the nuclear translocation of NF-B, following the TCR activation, in memory T cells isolated from human lung tumor and from nonmalignant chronic inXammatory tissues [21] . Another study demonstrated that TGF-inhibits phosphorylation and activation of ITK in normal CD4 + T cells resulting in the lack of CD4 + T cell diVerentiation into Th1/Th2 lineages [22] . In our study we demonstrated for the Wrst time, by Xow cytometry at a single cell level, that ITK phosphorylation following TCR stimulation was completely inhibited in tumor-associated CD8 + T cells as compared to splenic CD8 + T cells from the same tumor-bearing mice. These results suggest that the hyporesponsiveness of the CD8 + TILs to TCR stimulation could be due to the downregulation and/or inactivation of TCR signaling components such as ITK. The hyporesponsiveness of the CD8 + TILs could also be due to TGF-activity, since the inhibition of TGF-can reverse the reduced functionality of ITK.
An important event that could contribute to the induction of the hyporesponsiveness of the CD8 + TILs is the presence in the tumor microenvironment of CD4 + regulatory T cells (T REGs ). This hypothesis is supported by the already described intratumoral accumulation of CD4 + CD25 + T REG cells [7] and by the involvement of TGF-in the induction of Foxp3 expression in CD4 + CD25 ¡ T cells during T cell activation [19] .
Recently the concept has been emerging that CD8 + T REGs , as a subset of CD8 + T cells, may either inherently possess or be induced under speciWc activation conditions to exert suppressor activities [30] [31] [32] [33] . The compartmentalization of peripheral CD8 + T REGs in environments rich in IL-10 and TGF-, such as tumor microenvironments of tumor-bearing mice, has also been reported [34] . Moreover the CD8 + TILs, when stimulated with anti-CD3, produced high amounts of IFN-, a molecule that plays a crucial role in either the induction or the expression of CD8 + T REGs activity [35] . One can thus speculate that CD8 + T REGs may be present in the CD8 + TILs population contributing to the inhibition of CD8 + T cells activity in the tumor microenvironment.
We have also shown here for the Wrst time that Spred-1 expression can be related to impaired functionality of tumor-inWltrating CD8 + T cells. Spred-1 is a described inhibitor of growth factor-induced ERK kinases [23] . A previous study has shown the involvement of Spred-1 in tumor progression, in particular in human hepatocellular carcinoma where the downregulation of Spred-1 expression is one of the causes of the acquisition of malignant features by hepatic cells [25] . Spred-1 also plays an important role in lymphatic vessel development during embryogenesis and negatively regulates hematopoiesis suppressing stem-cellfactor (SFC)-induced and IL-3-induced ERK activation [24, 36] . Despite the fact that Spred-1 has been associated with the suppression of IL-5-dependent proliferation of CD4 + T cells in allergic asthma, there is no study addressing the role of Spred-1 in CD8 + T lymphocytes or in tumor-associated T cells [37] . ERK1/2 kinases activation is a crucial event in the signaling cascade of several growth factors in T cells; it is also a downstream event in the TCR signaling pathway leading to the activation and proliferation of T cells [38, 39] . We demonstrate here that Spred-1 is highly upregulated in the tumor-inWltrating CD8 + T cells. Our results illustrate that this upregulation of Spred-1 is accompanied by more than 60% reduction of ERK activity in the TILs' post-TCR activation. This ERK inhibition could be the consequence of the upstream impairment of TCR signaling components as well as the overexpression of Spred-1. Since ITK can function upstream to ERK inactivation, TGF-could suppress ERK by two diVerent mechanism, i.e., inhibition of ITK and/or induction of Spred-1.
Moreover, the inhibition of TGF-using a small molecule inhibitor SB505124 in an ex vivo tumor microenvironment led to a decreased expression level of Spred-1 in CD8 + T cells, as well as a restored ERK activity post-TCR activation, suggesting a correlation between the TGFpathway and Spred-1/ERK kinases. This correlation was also supported by our in vitro studies in which Spred-1 expression was increased only in eVector/memory CD8 + T cells after TGF-treatment.
The diVerential eVect of TGF-on the CD8 + T cells' diVerentiation status and activation history has been recently investigated in diVerent models [40, 41] . In tumor antigen-speciWc human memory CD8 + T cells TGF-attenuates the acquisition and expression of eVector function [40] ; in an in vitro mouse model, TGF-suppresses the activation of naïve CD8 + T cells but promotes their survival and function once they are antigen-experienced [41] .
In conclusion, we suggest that TGF-plays a pivotal role in T-cell anergy in the tumor microenvironment. High levels of TGF-in the tumor can result in downregulation of upstream TCR signaling components, accompanied by upregulation of Spred-1. This outcome leads to the inhibition of the ERK pathway, thereby contributing to the impairment of proliferation/cytokine production of tumorinWltrating CD8 + T cells. The results shown here may have important implications for the development of novel anti-tumor immune strategies based on the inhibition of TGF-by a small molecule inhibitor directed against the TGF-receptor; this strategy has the potential to be an alternative to the use of monoclonal antibody against TGF-. This strategy is based on the inhibition of Spred-1 function that blocks the ERK1/2 activation, which is an important event controlling several growth factor and cytokines cascades.
